CTRI/2020/08/027413进行中（未招募）4 期
A Multi Center Prospective Single Arm Post Market Surveillance Study to Evaluate the Safety and Efficacy of Botulinum Toxin Type A in Management of Moderate to Severe Facial Wrinkles - GB_BOT_001_20
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1) Male/Femles of 30-50 years of age
- •2) Subject who can and willing to provide written informed conscent
- •3)Subjects motivated and aesthetically conscious with moderate to severe facial wrinkles
- •4)Females of child bearing potential must have negative urine pregnancy test, must be practicing a medically acceptable method of birth control and not lactating
排除标准
- •1)Subjects with a known severe allergies manifested by a history of anaphylaxis or history or presence of multiple severe allergies
- •2) Subjects with a known allergy or sensitivity to any of the study medication or their components
- •3) Subjects having a mental or physical condition that would, in the opinion of the investigator, place the subject at an unacceptable risk or render the subject unable to meet the requirements of the protocol
- •4) Subjects has participated in another clinical study involving another investigational agent within 4 weeks of the start of this trial, or is planning participation in another clinical trial during the current study duration
- •5) Subjects with a history of vision loss not corrected by lenses, or LASIX surgery, glaucoma, retinal detachment, macular degeneration, history of multiple sclerosis or optic neuritis, or any uncontrolled eye disease 6) Subjects with acute infection 7. Subject with myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis or any other disease that might interfere with neuromuscular function
- •8) Concurrent use of aminoglycoside antibiotics that interfere with neuromuscular function
- •9) Subjects with history of previous injection of botulinum Toxin within eight months
- •10) Subjects with severe thin skin in treatment area as determined by the investigator
- •11) Subjects with infection at the injection site
- •12) Subjects having received anticoagulation, anti-platelet and thrombolytic treatment (eg Warfarin), anti-inflammatory drugs (NSAIDs aspirin, Ibuprofen, etc) or any other substance known to increase the coagulation time from 10 days pre to 3 days post injection
研究者
相似试验
已完成
不适用
Prospective Multi-Center, Single Arm Post-Market Study (PMS) of the Shockwave Medical, Inc. Coronary Lithoplasty® System in Coronary Arteriescoronary artery diseasecoronary artery narrowing100110821000759310003216NL-OMON46584Shockwave Medical Inc36
尚未招募
4 期
A clinical trial to assess the efficacy and safety of Formoterol fumarate and Fluticasone propionate powder for inhalation (Formoflo 250) in the patients withAsthmaCTRI/2023/08/056250upin Limited
尚未招募
不适用
Prospective, Multicenter, Post-market, Single Arm study to confirmthe performance of the RenzanTM Peripheral Stent System in treating Superficial Femoral and/or Popliteal artery diseasenarrowed leg arteriesperipheral disease10003216NL-OMON51143Terumo10
尚未招募
4 期
Observational Real World National Registry of Dafodil.CTRI/2022/07/044021Meril Life Sciences Pvt Ltd
招募中
不适用
Prospective, multicentre single-arm Post-Market Clinical Follow-up (PMCF) study to evaluate safety and performance of the BeYond Venous Self-Expanding StentI80.1I80.2I87.0Phlebitis and thrombophlebitis of femoral veinPhlebitis and thrombophlebitis of other deep vessels of lower extremitiesPostthrombotic syndromeDRKS00024063Bentley InnoMed GmbH110